Ella 6

[Daria]

ellaImportant Safety Information

The most common side effects of ella (ulipristal acetate) tablets include headache (18%), stomach pain (12%), nausea (12%), menstrual pain (9%), tiredness (6%), and dizziness (5%). ella should not be used if you know or suspected you are pregnant, and ella should not replace a regular method of birth control. If you become pregnant or have lower abdominal pain after taking ella, seek help from a healthcare provider right away as you could have a pregnancy outside the womb (ectopic pregnancy). ella may change when the next period comes. If your period is delayed beyond 1 week, you should be checked for pregnancy. Do not use ella if you are breastfeeding. Do not use ella more than once in a menstrual cycle. After taking ella if you do have sex again in the same cycle, use a reliable barrier method of birth control like condoms until your next period. Using ella with hormonal birth control such as birth control pills can reduce the effectiveness of both drugs to prevent pregnancy. If you are planning to use hormonal birth control, do so no sooner than 5 days after you take ella. Using some medicines and herbs may make ella less effective. Talk to your healthcare provider about all medicines and herbs you are taking before you use ella. ella does not protect against sexually transmitted infection or HIV.

Ella Bing immediately responded when I had questions about how many glasses I could customize for my groomsmen and executed it perfectly! Packaging was perfect for the glass in the packaging and everything arrived looking stellar!

I was visiting Florida and walked through your store. I noticed some aviator sunglass I really liked that I knew looked good on me. The look identical to Tom Cruises in Top Gun. I passed up on buying them in the store. When I got home I decided to find your website and buy them online and got a better price! I now have them in one of my cars and the look great on me.

I had ordered a Bow Tie and Wooden Sunglasses for the summer season. While what I had originally ordered ended up being out of stock, Brent did an amazing job finding products that were in stock that was both similar to what I had ordered and also what he figured I would like based on past orders.

I needed some accessories for a Kentucky Derby themed event and stopped into Ella Bing. Once before I was in need of cuff links prior to a meeting and this was the only store in the area that had them. I found the most amazing bow tie as well as a pocket square & hat from Bailey Hat company which totally completed my outfit. I received so many compliments and knew I made the right call. I highly recommend this shop!

After using ella, if a woman wishes to initiate hormonal contraception as a regular method, she can do so, no sooner than 5 days after the intake of ella and she should use a reliable barrier method until the next menstrual period [see Dosage and Administration (2.2), Drug Interactions (7.1 and 7.3) and Clinical Pharmacology (12.2)].

Progestin-containing contraceptives may impair the ability of ella to delay ovulation. Advise women to follow the instructions on the initiation or resumption of hormonal contraceptives after ella intake [see Dosage and Administration(2.2)].

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Drugs or herbal products that induce CYP3A4 decrease the plasma concentrations of ella, and may decrease its effectiveness [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3)]. Avoid co-administration of ella and drugs or herbal products such as:

Ella is contraindicated for use during an existing or suspected pregnancy. No signal of concern regarding pregnancy complications was found in postmarketing studies [see Data]. Isolated cases of major malformations in ella-exposed pregnancies were identified; however, the data are not sufficient to determine a risk for birth defects with inadvertent use of ella during pregnancy. Miscarriage was reported in 14% of the known pregnancy outcomes; a rate that is similar to the U.S. background rate for miscarriage. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Ella pregnancy exposure data was collected in the U.S. and Europe from 1999 to 2015 and analyzed post-marketing using data from interventional clinical trials, observational studies and pharmacovigilance reports. Known pregnancy outcomes were available for 462/784 pregnancies in which women received ella at doses of 30 mg or greater during the conception cycle or during pregnancy. Data of pregnancies with known outcome were analyzed prospectively for 272 cases and retrospectively for 190 cases. Pregnancy outcomes included 302 elective abortions (2 for fetal anomalies including 1 with trisomy 21), 63 spontaneous abortions, and 13 ectopic pregnancies. No maternal or fetal deaths were reported. 84 pregnancies continued until birth, with congenital anomalies reported in 5 infants, including 4 major malformations (2/4 with genetic syndromes). Although these data do not allow estimation of the prevalence rate of congenital anomalies associated with inadvertent use of ella in pregnancy or determination of a causal relationship between reported anomalies and ella, they show that ella-exposed pregnancies were not associated with a pattern of increased risk of adverse outcomes.

Ulipristal acetate was administered repeatedly to pregnant rats and rabbits during the period of organogenesis. Embryofetal loss was noted in all pregnant rats and in half of the pregnant rabbits following 12 and 13 days of dosing, at daily drug exposures 1/3 and 1/2 the human exposure, respectively, based on body surface area (mg/m2). There were no malformations of the surviving fetuses in these studies. Adverse effects were not observed in the offspring of pregnant rats administered ulipristal acetate during the period of organogenesis through lactation at drug exposures 1/24 the human exposure based on AUC. Administration of ulipristal acetate to pregnant monkeys for 4 days during the first trimester caused pregnancy termination in 2/5 animals at daily drug exposures 3 times the human exposure based on body surface area.

The breast milk of 12 lactating women following administration of ella was collected in 24-hour increments to measure the concentrations of ulipristal acetate and the active metabolite monodemethyl-ulipristal acetate in breast milk. The mean daily concentrations of ulipristal acetate in breast milk were 22.7 ng/mL [0-24 hours], 2.96 ng/mL [24-48 hours], 1.56 ng/mL [48-72 hours], 1.04 ng/mL [72-96 hours], and 0.69 ng/mL [96-120 hours]. The mean daily concentrations of monodemethyl-ulipristal acetate in breast milk were 4.49 ng/mL [0-24 hours], 0.62 ng/mL [24-48 hours], 0.28 ng/mL [48-72 hours], 0.17 ng/mL [72-96 hours], and 0.10 ng/mL [96-120 hours]. Using these data, a fully breastfed infant would receive approximately 4.1 mcg/kg of ulipristal acetate and monodemethyl-ulipristal acetate on Day 1 following drug administration and approximately 5.2 mcg/kg over a five day period following drug administration.

Progestin-containing contraceptives may impair the ability of ella to delay ovulation. Advise females to use a reliable barrier method for subsequent acts of intercourse until her next menstrual period.

Safety and efficacy of ella have been established in women of reproductive age. The clinical trials of ella enrolled 41 females under age 18, and a post-marketing observational study evaluating effectiveness and safety of ella in adolescents enrolled 279 females under age 18, including 76 under age 16 years. In these studies, the safety and efficacy profile observed in adolescents aged 17 and younger was similar to that in adults. Use of ella before menarche is not indicated.

The pharmacodynamics of ulipristal acetate depend on the timing of administration in the menstrual cycle. Administration in the mid-follicular phase causes inhibition of folliculogenesis and reduction of estradiol concentration.

Pharmacodynamic data showed that administration of ella to 34 women in the late follicular phase postponed follicular rupture for at least 5 days in all (100%) of 8 subjects who took ella before the luteinizing hormone (LH) surge and 11 (79%) of 14 subjects who took ella immediately before ovulation (when LH has already started to rise). However, treatment was not effective in postponing follicular rupture when administered on the day of LH peak.

3a8082e126